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ABSTRACT 
Signal transducers and activators of transcription (STAT) 3 and 5 are commonly constitutively 
activated in breast cancer. STAT5 can outcompete STAT3 and reduce cell proliferation and 
metastasis. STAT5 activation is stimulated by prolactin, a natural hormone that can be harmful at 
high levels. The aim of this study is to identify some possible previously developed drugs that 
mimic the effect of prolactin and STAT5 without the added risk in MDA-MB231 breast cancer 
cells. Using the CLUE database query app and STAT5 up- and downregulation signatures, three 
drugs (X, K, and M) were chosen based on their similarity in signatures to those of STAT5. 
These drugs were then analyzed for cell viability to determine dosage. qPCR was used to 
compare the expression of STAT5 target genes after drug treatment and the expression after 
STAT5 activation with prolactin. The drug K was found to show a similar impact on target gene 
expression to prolactin. Further research is required, but from this study K seems to be a 
promising option for stimulating STAT5 and improving breast cancer prognosis. 
